226 related articles for article (PubMed ID: 27319235)
41. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
42. Lenalidomide in multiple myeloma.
Kim Y; Schmidt-Wolf IG
Expert Rev Anticancer Ther; 2015 May; 15(5):491-7. PubMed ID: 25843431
[TBL] [Abstract][Full Text] [Related]
43. Role of thalidomide in the treatment of patients with multiple myeloma.
Morgan GJ; Davies FE
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S14-22. PubMed ID: 23827438
[TBL] [Abstract][Full Text] [Related]
44. Maintenance therapy for multiple myeloma.
McCarthy PL; Palumbo A
Hematol Oncol Clin North Am; 2014 Oct; 28(5):839-59. PubMed ID: 25212886
[TBL] [Abstract][Full Text] [Related]
45. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
46. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
Koeppen S
Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
[TBL] [Abstract][Full Text] [Related]
47. Clinical management of myeloma--state of the art.
Harousseau JL
Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182
[TBL] [Abstract][Full Text] [Related]
48. Lenalidomide in multiple myeloma.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
[TBL] [Abstract][Full Text] [Related]
49. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
[TBL] [Abstract][Full Text] [Related]
50. New pharmacotherapy options for multiple myeloma.
Mina R; Cerrato C; Bernardini A; Aghemo E; Palumbo A
Expert Opin Pharmacother; 2016; 17(2):181-92. PubMed ID: 26684262
[TBL] [Abstract][Full Text] [Related]
51. Management of older patients with multiple myeloma.
Gay F; Palumbo A
Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
[TBL] [Abstract][Full Text] [Related]
52. Continuous treatment with new agents for newly diagnosed multiple myeloma.
Zou Y; Sheng Z; Lu H; Yu J
Anticancer Drugs; 2013 Jun; 24(5):527-33. PubMed ID: 23511426
[TBL] [Abstract][Full Text] [Related]
53. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis.
Ailawadhi S; Frank RD; Advani P; Swaika A; Temkit M; Menghani R; Sharma M; Meghji Z; Paulus S; Khera N; Hashmi SK; Paulus A; Kakar TS; Hodge DO; Colibaseanu DT; Vizzini MR; Roy V; Colon-Otero G; Chanan-Khan AA
Cancer Med; 2017 Dec; 6(12):2876-2885. PubMed ID: 29105343
[TBL] [Abstract][Full Text] [Related]
54. A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.
Takemori N; Imai G; Hoshino K; Ooi A; Kojima M
J Med Case Rep; 2018 Feb; 12(1):40. PubMed ID: 29454372
[TBL] [Abstract][Full Text] [Related]
55. Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma.
Sheng Z; Liu G
Hematol Oncol; 2016 Jun; 34(2):102-7. PubMed ID: 25643940
[TBL] [Abstract][Full Text] [Related]
56. A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.
Ibata S; Sato T; Kuroda H; Nagamachi Y; Iyama S; Fujimi A; Kamihara Y; Konuma Y; Yoshida M; Tatekoshi A; Hashimoto A; Horiguchi H; Ono K; Murase K; Takada K; Miyanishi K; Kobune M; Hirayama Y; Kato J
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1041-1049. PubMed ID: 27738809
[TBL] [Abstract][Full Text] [Related]
57. Thalidomide and lenalidomide in multiple myeloma.
Mazumder A; Jagannath S
Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
[TBL] [Abstract][Full Text] [Related]
58. The role of maintenance therapy in the treatment of multiple myeloma.
Badros AZ
J Natl Compr Canc Netw; 2010 Feb; 8 Suppl 1():S21-7. PubMed ID: 20141671
[TBL] [Abstract][Full Text] [Related]
59. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Zangari M; Fink L; Zhan F; Tricot G
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
[TBL] [Abstract][Full Text] [Related]
60. The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma.
Hashimoto S; Kuroha T; Yano T; Sato N; Furukawa T
Intern Med; 2016; 55(20):3025-3028. PubMed ID: 27746443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
